When will the FDA approve Intellia Therapeutics' lonvo-z?
13.0 pts (24h)Health & MedicineOne-Off9mois
KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesAssez bien calibréProbabilité implicite actuelle
Before 2028 72%En tête parmi 3 options
Qualité du marché
38 / 100
Faible qualitéVolume 24h
884,7 €
Liquidité
2,6 k €
Liquidité moyenneÉcart
64.0 pt
Spread largeDonnées du marché
Mis à jour il y a 8 minutes
24 mars 26, 14:00 UTC1 juil. 27, 03:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
Will the FDA approve retatrutide?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsWill the FDA approve a psilocybin treatment during 2026?
FutuurRègles
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes.
Marchés ouverts
Health & Medicine
POLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume total
- 15,6 M €
- Volume 24h
- 18,3 k €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume total
- 1,6 M €
- Volume 24h
- 5,2 k €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 résultats de plus
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume total
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume total
- 916 k €
- Volume 24h
- 1,5 k €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 résultats de plus
- Volume total
- 863,6 k €
- Volume 24h
- 1 k €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Questions fréquentes
- Quelles sont les probabilités actuelles pour When will the FDA approve Intellia Therapeutics' lonvo-z? ?
- Kalshi cote Before 2028 à 72% au 8 septembre 2026.
- Quand When will the FDA approve Intellia Therapeutics' lonvo-z? sera-t-il résolu ?
- When will the FDA approve Intellia Therapeutics' lonvo-z? doit être résolu le 1 juillet 2027.
- Comment When will the FDA approve Intellia Therapeutics' lonvo-z? est-il réglé ?
- Kalshi règle ce marché comme suit : If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.